The global pelvic cancer induced hemorrhagic cystitis market is expected to reach an astounding US$11 billion by 2033. This represents an impressive growth trajectory from 2023’s value of US$2.1 billion, with a compound annual growth rate (CAGR) of 18.01% that is noteworthy.
PC-HC is a crippling side effect that can happen following therapy for pelvic cancer. It causes excruciating bladder hemorrhage and inflammation. Good PC-HC therapy options are in high need as the number of pelvic malignancies, including endometrial and cervical cancers, increases.
The crippling illness known as hemorrhagic cystitis results in bladder inflammation and bleeding. It may occur as a side effect of radiation therapy and chemotherapy, among other therapies for pelvic cancer. The rising incidence of pelvic cancer and the increased knowledge of hemorrhagic cystitis are the main factors propelling the market expansion.
Growing public awareness of early diagnosis and treatment for related conditions, coupled with a persistent trend toward unhealthy diets and sedentary lifestyles, are driving demand in the market. Thanks to advances in drug research, physicians can now inject drugs directly into ill tissues without compromising neighboring healthy cells. Patient compliance has increased as a result, and this is expected to support market expansion.
Obtain Your Sample Report Copy:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16245
The high research and development cost associated with the manufacturing of hemorrahagic cystitis treatment drugs, coupled with increased penetration of generic drugs, is likely to restrain market growth. However, technological advancements in drug development to manufacturing cost-effective and side-effect-free drugs are anticipated to create opportunities for industry movements. Moreover, the use of High approval rate of Ifosfamide and cyclophosphamide for use in a variety of malignancies, both in children and adults are driving the market for Haemorrhagic Cystitis. North America dominates the market for Pelvic Cancer induced Hemorrhagic Cystitis with market valuation of US$ 3.6 Billion, followed by APAC.
Key Takeaways
- North American Pelvic cancer induced hemorrhegic cystitis market is expected to reach US$ 3.6 Billion with a CAGR of 14.87% during the forecast period.
- With a CAGR of 15.1%, APAC is projected to be fastest growing market for this haemorrhagic cystitis.
- By treatment type, chemotherapy is expected to dominate the market with a 2/3rd segment share.
- Radiation therapy is anticipated to be a secondary treatment for hemorrhegic cystitis after Chemotherapy.
- High cost of treatments and side-effects in post-treatment period will restrict market growth.
- Adoption of combination therapies and novel therapies are expected to proliferate product demand.
- Technological advancements in drug development for treatment of pelvic induced hemorrhagic cystitis is anticipated to strengthen market footprint.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16245
Competitive Landscape
Key players in the Pelvic cancer induced hemorrhagic Cystitis Market are: Johnson & Johnson Services, Inc, Astellas Pharma Inc, Eli Lilly and Company, Sanofi, Ipsen Pharma, Bayer AG, AstraZeneca, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., Pfizer Inc.
- In April 2022, Pfizer made an equity investment worth USD 25 million in Zentalis Pharmaceuticals, Inc. This investment is expected to help Pfizer to leverage its development capabilities globally
- In May 2022, Pfizer entered a research collaboration agreement of two years with NetVation DL Medicine. This collaboration is anticipated to aid and advance Pfizer in its research activities
- In June 2022, Roche introduced a human papillomavirus (HPV) self-sampling solution that enables patients to perform HPV screening in the presence of a healthcare worker. This is expected to expand the company’s cancer screening solution line-up
- In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio.
Unlock In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16245
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Segments Profiled in the Pelvic Cancer Induced Hemorrhagic Cystitis Market Industry Survey
By Treatment:
- Bone Marrow Transplant
- Chemotherapy
- Cyclophosphamide
- Ifosfamide
- Radiation Therapy
- Other Treatments
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
